Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN.
Jun 5 2011 Versartis Long-Term Preclinical Safety Data for VRS-317 Presented at ENDO 2011
Mar 28 2011 Versartis Initiates Phase 1 Clinical Trial of VRS-317 Monthly Human Growth Hormone Therapy
Feb 16 2011 Versartis Completes $21 Million Series B Financing
The company is interested in exploring partnerships on our products to accelerate the development process and ensure successful commercialization.
